Acute myeloid leukaemia+1
Not recruitingStudy Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation
Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation
- Disease:Acute myeloid leukaemiaMyelodysplastic syndrome with excess blasts
- Substances:GilteritinibMidostaurin
France- Participants:18–64 years · 65+ years
- Substances:Gilteritinib
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting











